Search

Displaying results 3701 - 3710 of 4539 in total
  1. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. … Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine.

  2. Drug

    Triazolam

    go.drugbank.com/drugs/DB00897
    ApprovedInvestigational

    Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

  3. Drug

    Nicardipine

    go.drugbank.com/drugs/DB00622
    ApprovedInvestigational

    A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the ...

  4. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate ...

  5. Drug

    Nitrendipine

    go.drugbank.com/drugs/DB01054
    ApprovedWithdrawn

    Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natri...

  6. Drug

    GRAd-COV2

    go.drugbank.com/drugs/DB16428
    Investigational

    GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].

  7. Drug

    BB-301

    go.drugbank.com/drugs/DB17011
    Investigational

    [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062]

  8. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.

  9. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.

  10. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial